riluzole has been researched along with Mood Disorders in 3 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate." | 6.44 | Riluzole in the treatment of mood and anxiety disorders. ( Banasr, M; Bloch, M; Coric, V; Krystal, JH; Pittenger, C; Sanacora, G, 2008) |
| "Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate." | 2.44 | Riluzole in the treatment of mood and anxiety disorders. ( Banasr, M; Bloch, M; Coric, V; Krystal, JH; Pittenger, C; Sanacora, G, 2008) |
| "Riluzole has been shown to reverse glutamate-mediated impairments in neuronal plasticity and to stimulate the synthesis of brain derived neurotrophic factor." | 2.43 | Glutamate modulators as novel interventions for mood disorders. ( Keegan, K; Mathew, SJ; Smith, L, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pittenger, C | 1 |
| Coric, V | 1 |
| Banasr, M | 1 |
| Bloch, M | 1 |
| Krystal, JH | 1 |
| Sanacora, G | 1 |
| Machado-Vieira, R | 1 |
| Manji, HK | 1 |
| Zarate, CA | 1 |
| Mathew, SJ | 1 |
| Keegan, K | 1 |
| Smith, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder[NCT03017508] | Phase 2/Phase 3 | 22 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Measure Description: In the Visual Analogue Scale (VAS) participants are presented with a straight horizontal line of 100 mm in length and asked to mark the placement that would best describe the intensity of the anxiety felt at that moment. The left end (0mm) represents no anxiety and the right end (100mm) represents the worst anxiety ever felt by the participant.The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks, generating a numerical score along a continuum" (NCT03017508)
Timeframe: up to 60 minutes
| Intervention | millimeters (units on a scale) (Mean) |
|---|---|
| BHV-0223 (Sublingual Riluzole) | 54.3 |
| Placebo | 62.6 |
3 reviews available for riluzole and Mood Disorders
| Article | Year |
|---|---|
Riluzole in the treatment of mood and anxiety disorders.
Topics: Animals; Anxiety Disorders; Excitatory Amino Acid Antagonists; Humans; Models, Biological; Mood Diso | 2008 |
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Topics: Animals; Brain; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Ketamine; Mood Disorders; | 2009 |
Glutamate modulators as novel interventions for mood disorders.
Topics: Animals; Antidepressive Agents; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mood Disorders; | 2005 |